INTRODUCTION
Tuberculosis (TB) remains a worldwide public health problem, which has been made even more urgent by the emergence of multi-and extensively drug resistant strains and co-morbidities that increase its incidence. Different kinds of strategies are needed, to reduce TB burden on society, to improve its prevention and control of the illness, which include new drugs for treatment and new vaccines to prevent the progression of TB. BCG is the only current vaccine available, which provides protection against disseminated TB (meningitis and disseminated tuberculosis) during childhood. However, BCG is not effective in preventing pulmonary TB (WHO 2017) .
Novel TB vaccine candidates undergo a series of tests involving animal models to determine several factors such as their ability to induce immune response and to reduce the mycobacterial burden after infection with virulent M. tuberculosis (Gupta and Katoch 2009) . Mouse and guinea pig are animal models of TB that are routinely used to evaluate vaccines. The two models differ, however, they provide useful information to determine whether a new strain might be a good candidate to replace BCG. Mice are used to provide immunogenicity and protective immunity information during early vaccine development, whereas results generated in Hartley guinea pigs are useful for determining the capacity of a vaccine candidate to prevent disease. Although mice are widely used in evaluating vaccines, TB in guinea pig produces granulomas similar to those seen in humans and characteristic of primary TB (Hunter et al. 2018) . Also, the transmission mechanisms of TB infection and epidemiology evaluated in guinea pigs have shown their susceptibility to infection via bacilli droplets at low doses in laboratory conditions or in contact with human patients with active TB, emulating TB infection in humans (Donald et al. 2018) . On the other hand, a humanized mouse model has been proposed to complement the data displayed in mice and guinea pig models to provide further evidence that a vaccine can induce a human-like T-cell response (Grover et al. 2017) . In guinea pigs, vaccine studies comprise two stages to provide evidence of protection. The first one is a shortterm infection where guinea pigs are vaccinated and infected with a low dose aerosol of M. tuberculosis and the CFU determined at 4 weeks post-infection. The second, is a long-term survival study where disease symptoms are monitored as survival and histopathological changes in the lungs (Grover et al. 2012) . The results of a good vaccine candidate should highlight that it prevents or significantly delays weight loss and limit pulmonary pathology and moreover prolong survival of an infected guinea pig. Also, it is expected that immunogenicity and protective efficacy should be equivalent to or better than BCG in mouse and guinea pig models (Clark, Hall and Williams 2015) .
Several research groups around the world have developed different vaccine evaluation protocols using the guinea pig model. In most cases, its application has been quite robust, and, in some cases, it has been comparable with the results displayed in mice (Grover et al. 2012) . Evidently, it is necessary to keep in mind the doses used for challenge as well as the M. tuberculosis strains used to produce infection, when comparing vaccine candidates tested in different protocols (Williams et al. 2005) .
The residual virulence of new whole-cell, live-attenuated vaccine candidates can also be tested in guinea pigs, as well as in immunodeficient mice. In this approach, it is common to delete a gene from the mycobacterial genome, considered to encode for a virulence factor, in an attempt to reduce its capacity to produce disease in the host. However, in some instances, such deletion results in decreased efficacy of protection of the resulting vaccine candidates. Such was the case of a PDIM/PGL-deficient strain of BCG Pasteur in which fadD28 was deleted. Vaccination with this BCG mutant resulted in an increase in bacillary load and greater tissue damage in the lung compared to the control strain (Tran et al. 2016) . In contrast, the design of vaccines introducing immunodominant antigens seems to increase the immune response, as is the case when inserting the gene for perfringolysin O of Clostridium perfringens in the BCG strain (Sun et al. 2009 ).
BCG BCG1419c is a strain deleted of the BCG1419c gene, which encodes for a protein with phosphodiesterase activity involved in c-di-GMP second messenger degradation, a molecule implicated in biofilm formation and virulence factors production (Tamayo, Pratt and Camilli 2007) . The BCG BCG1419c vaccine candidate has shown improved efficacy as compared with BCG in controlling chronic infection in diverse mice models, including increased capacity to induce T CD4 + IFNγ + and T CD8 + IFNγ + lymphocytes, as well as reducing M. tuberculosis replication and lung pathology in vaccinated and infected in BALB/c mice (Pedroza-Roldan et al. 2016) . It also reduced production of IL-6, and lung pathology in vaccinated and infected C57BL/6 mice, more effectively than parental BCG (Flores-Valdez et al. 2018) . Taking into account the increased susceptibility to TB of guinea pigs as compared to mice, we decided to test the capacity of BCG BCG1419c to reduce lung pathology during TB infection, and replication of M. tuberculosis in lungs, lymphatic nodes and spleens, in time-course manner, and found that in the latter, there was a transient improvement in reducing bacillary loads, as compared to parental BCG.
METHODS
BCG culture and preparation for immunization. BCG Pasteur wild type and BCG BCG1419c were grown in Middlebrook 7H9 medium supplemented with 10% OADC, 0.2% glycerol, 0.05% Tween 80 under static conditions, at 37
• C and 5% CO 2 at a starting OD600 nm = 0.05. Cultures were incubated for 1 week until they reached OD600 nm = 0.7. Then, cells were centrifuged at 5000 rpm for 5 min. Pellets were washed twice with PBS 1X, and cells were resuspend in PBS 1X in one-third of the initial volume, and frozen in dry ice and kept at −80 • C. We then shipped frozen cell pellets to Colorado State University (CSU) under dry ice. In CSU, cell suspensions were quantified by determining viable colony forming units by plating serial dilutions onto Middlebrook 7H10 10% OADC agar plates, containing 0.5% glycerol, and incubated 3 weeks at 37
• C, 5% CO 2 .
Vaccination and challenge
The studies were approved by the Animal Care and Usage Committee (ACUC) at CSU. Thirty six female guinea pigs were purchased from the Charles River Company when ∼350 g in weight.
They were acclimated and allowed to grow to 500 g, and then 12 animals per group were vaccinated with 10 4 CFU of BCG Pasteur or BCG BCG1419c via the intradermal route. A control group of 12 guinea pigs extra was administered with saline solution. At 6 weeks post-vaccination guinea pigs were challenged with an aerosol infection with H37Rv calibrated to deliver 10-15 bacilli into the lungs. At 30, 60 and 90 days of the infection, animals were euthanized, and their lungs, spleens and lymph nodes were aseptically removed. Individual whole lung lobes were homogenized and serial dilutions plated on nutrient 7H11 agar; these were incubated for 21 days at 37
• C in humidified air before counting and calculating organ bacterial loads. Data were analyzed using ANOVA test to determine statistical significances between mean differences between groups at a 95% confidence interval. Tissue sections were also prepared and stained with hematoxylin and eosin, to evaluate lung pathology as previously described (Drumm et al. 2009 ). Briefly, the semiquantitative scoring system evaluates the percentage of lung affected, primary and secondary lesions, mineralization, fibrosis and necrosis, all graded from 0 to 4 (corresponding to 0, 25, 50, 75 and > 75% involvement for percent lung affected and secondary lesions, and presence/absence, extent, coalescence or not of lesions, for primary lesions, mineralization, fibrosis and necrosis). The maximum total lung score results from the sum of all these factors, and can reach a value up to 24.
RESULTS
A BCG Pasteur strain deficient in the BCG1419c gene (BCG BCG1419c) was tested in comparison with BCG Pasteur wild type as control. As BCG BCG1419c has shown improved protection against chronic TB in mice as compared to parental BCG without compromising its safety of use (Pedroza-Roldan et al. 2016; Flores-Valdez et al. 2018) , in this study, we compared the efficacy of BCG BCG1419c in the highly susceptible guinea pig model after challenge with the virulent M. tuberculosis strain H37Rv. When comparing bacterial load in the lungs with that of saline controls [mean CFU/lung 5.5-log 10 ], both BCG BCG1419c [mean CFU/lung 4-log 10 , P < 0.003] and BCG [mean CFU/lung 3.5-log 10, P < 0.001] conferred a significant reduction of M. tuberculosis replication at 30 days post-infection, although this protective advantage was less evident at day 60 and 90 post-infection (Fig. 1A) .
In spleens, at 30 days post-infection, both BCG BCG1419c and BCG vaccination [mean CFU 2-log 10 , P < 0.001] resulted in significant reduction of M. tuberculosis replication compared to saline control (mean CFU 5-log 10 ), which was sustained after 2 months post-infection only in guinea pigs vaccinated with BCG BCG1419c (Fig. 1B , mean CFU 2-log 10 , P < 0.001 vs BCG mean CFU 3.5-log 10 ), although by day 90 such a difference was lost.
Finally, in lymph nodes, only BCG (mean CFU 2.2-log 10 ) provided significant protection compared with BCG BCG1419c (mean CFU 4.8-log 10 ) and saline control (mean CFU 6-log 10 ) [P < 0.001], with later stages showing no differences for any group (Fig. 1C) .
Microscopic assessment of lungs revealed multiple granulomatous lesions in the saline group, including central necrosis and mineralization of some granulomas ( Fig. 2A) . By day 90 postinfection this had progressed to large coalescing granulomas and secondary lesions. In contrast, lung lesions were limited in the BCG and BCG BCG1419c groups and only slightly worse at later timepoints in the animals given the BCG BCG1419c vaccine candidate compared to the BCG group ( Fig. 2A) .
For particular lesion types, at 30-days post-infection, the BCG BCG1419c-vaccinated group approached statistical significance compared to saline control (P = 0.06), while the BCG Pasteur-vaccinated group was not different from saline controls (P = 0.14) in preventing formation of primary lesions. Only the BCG-vaccinated group was different from the saline controls with regards to necrosis of the granulomas (P = 0.0232). Finally, for total lung score, both BCG strains afforded significant protection compared with saline controls (P < 0.0001) with no difference between them. (P = 0.7199) (Fig. 2B) .
At day 60 post-infection, only total lung score was significantly different (P < 0.0001) for vaccinated vs non-vaccinated groups, and also for BCG vs BCG BCG1419c groups. As for individual lesion types, there were some that were close to statistical difference (P = 0.06) such as primary lesions (BCG BCG1419c vs saline) and fibrosis (saline vs BCG; BCG vs BCG BCG1419c). Overall, these results suggest an improved protection at this time point for BCG-vaccinated guinea pigs (Fig. 2C) . Although it seemed that parental BCG afforded a slightly improved protection by day 60 post-infection, both BCG strains were equally effective in reducing lung pathology by 90 days post-infection (P < 0.0001). (Fig. 2D) 
DISCUSSION
The guinea pig is highly susceptible to infection with low numbers of M. tuberculosis and is considered a more stringent test of the ability of a vaccine to prevent disease and deaths (Gupta and Katoch 2009; Clark, Hall and Williams 2015) . However, intriguingly, no direct correlation was found between the capacity of transmission of M. tuberculosis clinical isolates obtained from South Africa and their capacity to grow in lungs from infected guinea pigs (Shanley et al. 2018) , therefore raising questions about the convenience of including more than one M. tuberculosis strain in studies of vaccine efficacy. On the other hand, some years ago, it was demonstrated that vaccination of guinea pigs with a recombinant BCG strain, termed rBCG30, which overexpresses Ag85B, resulted in increased protection against M. tuberculosis challenge compared to the parental BCG strain (Tullius et al. 2008) . days post-infection. Statistically significant differences compared with saline control were found at: (A) 30 days post-infection for necrosis in BCG-vaccinated guinea pigs ( * P = 0.0232) as well as for total lung score for both BCG strains ( * * P < 0.001); (B) 60 days post-infection for total lung score for both BCG strains ( * P < 0.001) and also for BCG-vs BCG BCG1419c-vaccinated guinea pigs ( * * P < 0.001); (C) 90 days post-infection for both BCG-vaccinated groups in total lung score ( * P < 0.001). For each time point, four animals were euthanized, and a representative figure from each group and time point is shown.
In the present study, we observed that BCG and BCG BCG1419c seem to be comparable in their efficacy to reduce M. tuberculosis H37Rv replication in lungs of infected guinea pigs, with an apparent trend for lower bacillary burden in animals vaccinated with parental BCG (Fig. 1A) although this was not statistically significant. We did, however, observe a dramatic reduction in hematogenous spread of M. tuberculosis to the spleen at day 60 post-infection in animals vaccinated with BCG BCG1419c in comparison with BCG (mean 1.5-log 10 lower than BCG, Fig. 1B ). Such reduction is superior to the one promoted by rBCG30, reported to be around 0.6-log 10 at 10 weeks (70 days) post-infection. It is worth noting that the immunization dose used was different in our study compared to the report by Tullius et al. (10 4 vs 10 6 CFU, respectively), as was the M. tuberculosis strains used for challenge (H37Rv vs Erdman, respectively). Recently, a triple knock-out M. tuberculosis-derived vaccine candidate was shown to be unable to reduce hematogenous spread to spleens of M. tuberculosis in infected guinea pigs (Chauhan et al. 2013) , resulting in tissue damage. This led the research group to additionally delete the bioA gene, producing the quadruple mutant, vaccine candidate strain Mtb mmsb, which despite containing most of the antigenic repertoire of M. tuberculosis, failed to provide protection even similar to that afforded by vaccination with BCG (Bahal et al. 2018 ).
If we compare data available for the MTBVAC vaccine candidate from a study conducted in guinea pigs, where experimental conditions closely resemble those reported in the present work [immunization dose (10 4 CFU), M. tuberculosis strain and dose used for challenge (H37Rv, 10 2 CFU), and time postinfection (close to 1 month post-infection)], we can see that the BCG BCG1419c vaccine candidate reduced bacillary loads in lungs and spleens ( Fig. 1A and B) to levels very similar to those attained by immunization with MTBVAC (Arbues et al. 2013 ) (ca. 1.5-log 10 in lungs and ca. 3 to 4-log 10 in spleens vs non-vaccinated animals). However, a direct comparison MTB-VAC/BCG was not reported by Arbues et al., nor was infection monitored at additional time points. In a recent report, vaccination of guinea pigs with a modified BCG Japan derivative, where the phoPR genes were overexpressed, resulted in no statistical difference in controlling replication in lungs and spleen of infected animals compared with the parental strain harboring the plain vector (Ahn et al. 2018) . These results bear similarity to our own, in other words, we found no difference compared with BCG wild type in reducing M. tuberculosis replication in lungs (Fig. 1A) . Nevertheless, for BCG BCG1419c we observed a dramatic reduction of CFU in spleen (Fig. 1B) at a similar time point post-infection (8 weeks in Ahn et al., vs 60 days in this work). It is worth mentioning that these results were obtained using 5 × 10 4 BCG CFUs for vaccination (similar to the dose used in our own experiments with BCG BCG1419c) and 5 × 10 3 CFU M. tuberculosis H37Rv were used for challenge (10 2 CFU higher than our infectious dose). When the same BCG::phoPR strain was used in another experiment, where the infectious dose was reduced from 5 × 10 3 CFU to 1 × 10 3 CFU of M. tuberculosis H37Rv per animal, enhanced survival and reduced lung pathology of animals surviving the challenge was found (Ahn et al. 2018) . In future studies, we aim to compare the capacity of BCG BCG1419c to prolong survival time of vaccinated guinea pigs to that of parental BCG. In terms of reducing hematogenous spread of M. tuberculosis in infected guinea pigs, a 2-log 10 reduction has been observed for CFU numbers recovered from the spleens of BCG::ESAT-L28A/L29S vaccinated animals as compared to BCG-vaccinated group at 4 weeks post-infection (Bottai et al. 2015) . This is comparable to what we observed with BCG BCG1419c. According to our results, protection vs spread to the spleen was extended up to 60 days post-infection, constituting an apparent advantage of our modified BCG vaccine candidate in terms of reducing dissemination upon vaccination and challenge with M. tuberculosis. Furthermore, lung pathological changes were diminished to a comparable degree in both the BCG and BCG BCG1419c-vaccinated animals, corroborating the protective efficacy of this mutant against a virulent strain of M. tuberculosis. Of course, it is intriguing to see that such protection was completely lost at day 90 post-infection for BCG BCG1419c, although no data is available at this time point for MTBVAC and BCG::ESAT-L28A/L29S.
In summary, BCG BCG1419c is as effective as BCG in protecting guinea pigs from lung infection, and is also able to significantly reduce spread to the spleens up to 60 days post-infection.
It should be worth to mention that the mutant produces more biofilm that the WT (BCG) (Flores-Valdez et al. 2015) . This would be the rational of this vaccine design, and it follows an approach different from all other vaccine candidates under preclinical and clinical trials. It would be of particular relevance to evaluate this BCG strain in a revaccination scheme as reported by Clark et al. (2017) , given that when used as therapeutic vaccine in B6D2F1 mice already infected with M. tuberculosis, BCG BCG1419c was significantly better than BCG in preventing reactivation from latent-like infection (Pedroza-Roldan et al. 2016) .
We think that further studies about the efficacy of BCG BCG1419c to modify survival time after challenge with M. tuberculosis in guinea pigs, as well as other preclinical studies (immunogenicity, lack of virulence when applied as 50-times the dose applied to human beings, among others) are necessary to more comprehensively evaluate this vaccine candidate, including different doses of BCG BCG1419c or changing its administration route, to evaluate whether the protection vs dissemination could be prolonged further than 60 days post-infection.
